{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:38:39Z","timestamp":1793723919439,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11912-022-01350-9","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T06:09:48Z","timestamp":1672034988000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-4951","authenticated-orcid":false,"given":"Bashir","family":"Al Hussein Al Awamlh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"issue":"6","key":"1350_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784\u201395. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.001.","journal-title":"Eur Urol"},{"key":"1350_CR2","unstructured":"Bladder cancer statistics. 2020. https:\/\/www.wcrf.org\/cancer-trends\/bladder-cancer-statistics. Accessed 22 Aug 2022."},{"issue":"1","key":"1350_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1350_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 Update. Eur Urol. 2019;76(5):639\u201357. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016.","journal-title":"Eur Urol"},{"issue":"4","key":"1350_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016;196(4):1021\u20139. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049.","journal-title":"J Urol"},{"issue":"6","key":"1350_CR6","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/s0022-5347(05)68075-5","volume":"162","author":"B Leblanc","year":"1999","unstructured":"Leblanc B, Duclos AJ, Benard F, Cote J, Valiquette L, Paquin JM, et al. Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol. 1999;162(6):1946\u201350. https:\/\/doi.org\/10.1016\/s0022-5347(05)68075-5.","journal-title":"J Urol"},{"issue":"1","key":"1350_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"J Palou","year":"2012","unstructured":"Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol. 2012;62(1):118\u201325. https:\/\/doi.org\/10.1016\/j.eururo.2011.10.029.","journal-title":"Eur Urol"},{"issue":"3","key":"1350_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","volume":"60","author":"S van den Bosch","year":"2011","unstructured":"van den Bosch S, Alfred WJ. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60(3):493\u2013500. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.045.","journal-title":"Eur Urol"},{"issue":"5","key":"1350_CR9","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195\u2013203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016.","journal-title":"J Urol"},{"issue":"3","key":"1350_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031.","journal-title":"Eur Urol."},{"issue":"3","key":"1350_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"MD Shelley","year":"2001","unstructured":"Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209\u201316. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02306.x.","journal-title":"BJU Int"},{"key":"1350_CR12","unstructured":"Bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and.\u00a0Accessed 22 Aug 2022."},{"key":"1350_CR13","unstructured":"Important message about the BCG shortage. 2020. https:\/\/www.auanet.org\/about-us\/bcg-shortage-info.\u00a0Accessed 22 Aug 2022."},{"key":"1350_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. https:\/\/doi.org\/10.3389\/fphar.2017.00561.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1350_CR15","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","volume":"25","author":"K Fukumoto","year":"2018","unstructured":"Fukumoto K, Kikuchi E, Mikami S, Hayakawa N, Matsumoto K, Niwa N, et al. Clinical role of programmed cell death-1 expression in patients with non-muscle-invasive bladder cancer recurring after initial Bacillus Calmette-Guerin therapy. Ann Surg Oncol. 2018;25(8):2484\u201391. https:\/\/doi.org\/10.1245\/s10434-018-6498-2.","journal-title":"Ann Surg Oncol"},{"key":"1350_CR16","unstructured":"FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer. 2020.\u00a0https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-bcg-unresponsive-highrisk-non-muscle-invasive-bladder-cancer. Accessed 20 Aug\u00a02022."},{"issue":"7","key":"1350_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(21)00147-9. (Key study that led the FDA to approve pembrolizumab for BCG-unresponsive CIS.)","journal-title":"Lancet Oncol"},{"issue":"10","key":"1350_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/fon-2019-0817","volume":"16","author":"AM Kamat","year":"2020","unstructured":"Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, et al. KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC. Future Oncol. 2020;16(10):507\u201316. https:\/\/doi.org\/10.2217\/fon-2019-0817.","journal-title":"Future Oncol"},{"key":"1350_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.08.004","author":"K Meghani","year":"2022","unstructured":"Meghani K, Cooley LF, Choy B, Kocherginsky M, Swaminathan S, Munir SS, et al. First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to Bacillus Calmette-Guerin. Eur Urol. 2022. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.004.","journal-title":"Eur Urol"},{"issue":"15","key":"1350_CR20","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2021.39.15_suppl.4541","volume":"39","author":"PC Black","year":"2021","unstructured":"Black PC, Tangen C, Singh P, McConkey DJ, Lucia S, William TL, et al. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). ASCO2021. J Clin Oncol. 2021;39(15):4541\u20134541. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4541.","journal-title":"J Clin Oncol"},{"key":"1350_CR21","doi-asserted-by":"publisher","unstructured":"Roupret M, Neuzillet Y, Bertaut A, Pignot G, Houede N, Champiat S, et al. ALBAN: an open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37). J Clin Oncol.\u00a02019;37(15).\u00a0https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS4589.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4589"},{"key":"1350_CR22","doi-asserted-by":"publisher","unstructured":"Shore ND, Powles T, Bedke J, Galsky MD, Kopyltsov E, Necchi A, et al. A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Gu\u00e9rin, unresponsive high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B. ASCO Annual Meeting. J Clin Oncol. 2022;40(16) TPS4614\u2013TPS4614.\u00a0https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS4614.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4614"},{"key":"1350_CR23","doi-asserted-by":"publisher","unstructured":"Santis MD, Abdrashitov R, Hegele A, Kolb M, Parker S, Redorta JP, et al. A phase III, randomized, open-label, multicenter, global study of durvalumab and Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in high-risk, BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC). ASCO Genitourinary Cancers Symposium2019. J Clin Oncol. 2019;37(7). https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.TPS500.","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS500"},{"key":"1350_CR24","doi-asserted-by":"publisher","unstructured":"Gurram S, Bellfield S, Dolan R, Walter B, Merino M, Niglio S,\u00a0Bethesda AA, Agarwal P, Valera V. Interim analysis of a phase I single-arm study of the combination of durvalumab (Medi4736) and vicinium (Oportuzumab Monatox, Vb4-845) in subjects with high-grade non-muscle-invasive bladder cancer previously treated with Bacillus Calmette-Guerin (Bcg) (NCT03258593).\u00a02021;206(Supplement 3):e120\u2013e120. https:\/\/doi.org\/10.1097\/JU.0000000000001977.04.","DOI":"10.1097\/JU.0000000000001977.04"},{"key":"1350_CR25","doi-asserted-by":"publisher","unstructured":"Shore N, O\u2019Donnell M, Keane T, Jewett MAS, Kulkarni GS, Dickstein R, et al. Phase 3 results of vicinium in BCG-unresponsive non-muscle invasive bladder cancer. AUA2020. https:\/\/doi.org\/10.1097\/JU.0000000000000823.02.","DOI":"10.1097\/JU.0000000000000823.02"},{"key":"1350_CR26","unstructured":"Sesen Bio receives complete response letter from FDA for Vicineum\u2122 (oportuzumab monatox-qqrs). 2021.\u00a0https:\/\/ir.sesenbio.com\/news-releases\/news-release-details\/sesen-bio-receives-complete-response-letter-fda-vicineumtm. Accessed\u00a09\/1\/2022."},{"issue":"3","key":"1350_CR27","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.21873\/anticanres.11458","volume":"37","author":"T Hudolin","year":"2017","unstructured":"Hudolin T, Mengus C, Coulot J, Kastelan Z, El-Saleh A, Spagnoli GC. Expression of indoleamine 2,3-dioxygenase gene is a feature of poorly differentiated non-muscle-invasive urothelial cell bladder carcinomas. Anticancer Res. 2017;37(3):1375\u201380. https:\/\/doi.org\/10.21873\/anticanres.11458.","journal-title":"Anticancer Res"},{"key":"1350_CR28","doi-asserted-by":"publisher","unstructured":"Hahn NM, Chang S, Meng M, Shore ND, Konety BR, Steinberg GD, et al. A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT. ASCO2020. J Clin Oncol 2020;38(15). https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS5090.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5090"},{"issue":"7","key":"1350_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/14712598.2020.1738379","volume":"20","author":"KM Knudson","year":"2020","unstructured":"Knudson KM, Hodge JW, Schlom J, Gameiro SR. Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opin Biol Ther. 2020;20(7):705\u20139. https:\/\/doi.org\/10.1080\/14712598.2020.1738379.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"1350_CR30","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","volume":"40","author":"K Chamie","year":"2022","unstructured":"Chamie K, Chang SS, Gonzalgo M, Kramolowsky EV, Sexton WJ, Bhar P, et al. Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). ASCO2022. J Clin Oncol. 2022;40(6):4508\u20134508. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4508.","journal-title":"J Clin Oncol."},{"key":"1350_CR31","unstructured":"ImmunityBio Announces FDA Acceptance of biologics license application for N-803 in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ. N-803 study showing a complete response rate of 71% with a median duration of 24 months for CIS patients. https:\/\/immunitybio.com\/immunitybio-announces-fda-acceptance-of-biologics-license-application-for-n-803-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ\/2022.\u00a0Accessed 24 Aug 2022."},{"issue":"3","key":"1350_CR32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","volume":"172","author":"MA O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell MA, Lilli K, Leopold C, National Bacillus Calmette-Guerin\/interferon phase 2 investigator G. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol. 2004;172(3):888\u201393. https:\/\/doi.org\/10.1097\/01.ju.0000136446.37840.0a.","journal-title":"J Urol."},{"issue":"1","key":"1350_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(20)30540-4. (Nadofaragene firadenovec study showing a complete response rate of 53% at 3 months for BCG-unresponsive CIS.)","journal-title":"Lancet Oncol"},{"key":"1350_CR34","unstructured":"FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer.\u00a02022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-first-adenoviral-vector-based-gene-therapy-high-risk-bacillus-calmette-guerin. Accessed 21 Dec\u00a02022."},{"issue":"10","key":"1350_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Urol Oncol. 2018;36(10):440\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2017.07.005.","journal-title":"Urol Oncol"},{"key":"1350_CR36","doi-asserted-by":"publisher","unstructured":"Uchio EM, Lamm DL, Shore ND, Kamat AM, Tyson M, Tran B, et al. A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). ASCO Genitourinary Cancers Symposium2022. J Clin Oncol. 2022;40(6). https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS598.","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS598"},{"issue":"16","key":"1350_CR37","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","volume":"40","author":"Roger Li","year":"2022","unstructured":"Li Roger, Steinberg Gary D, Uchio Edward M, Lamm Donald L, Shah Paras, Kamat Ashish M, et al. CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG) ASCO2022. J Clin Oncol. 2022;40(16):4597\u20134597. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4597.","journal-title":"J Clin Oncol."},{"issue":"10","key":"1350_CR38","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archotol.128.10.1137","volume":"128","author":"CM Giguere","year":"2002","unstructured":"Giguere CM, Bauman NM, Sato Y, Burke DK, Greinwald JH, Pransky S, et al. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg. 2002;128(10):1137\u201344. https:\/\/doi.org\/10.1001\/archotol.128.10.1137.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"5C","key":"1350_CR39","first-page":"3295","volume":"24","author":"Y Ryoma","year":"2004","unstructured":"Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res. 2004;24(5C):3295\u2013301. (Phase 1 of a new therapeutic agent that has not been tested prior for non-muscle invasive cancer.)","journal-title":"Anticancer Res"},{"key":"1350_CR40","doi-asserted-by":"publisher","unstructured":"Bandari JJZ, Belani K, Brown E, Metcalf M, Nanayakkara N. Phase 1a\/b safety study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer (ADVANCED-1). ASCO2022. J Clin Oncol. 2022;40(6): TPS4620-TPS4620. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS4620.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4620"},{"issue":"1","key":"1350_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/BLC-150008","volume":"1","author":"RL Steinberg","year":"2015","unstructured":"Steinberg RL, Thomas LJ, O\u2019Donnell MA, Nepple KG. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive Bladder Cancer. Bladder Cancer. 2015;1(1):65\u201372. https:\/\/doi.org\/10.3233\/BLC-150008.","journal-title":"Bladder Cancer"},{"issue":"3","key":"1350_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/JU.0000000000002740","volume":"208","author":"IM McElree","year":"2022","unstructured":"McElree IM, Steinberg RL, Martin AC, Richards J, Mott SL, Gellhaus PT, et al. Sequential intravesical gemcitabine and docetaxel for Bacillus Calmette-Guerin-naive high-risk nonmuscle-invasive bladder cancer. J Urol. 2022;208(3):589\u201399. https:\/\/doi.org\/10.1097\/JU.0000000000002740.","journal-title":"J Urol"},{"key":"1350_CR43","doi-asserted-by":"publisher","unstructured":"Patel S, Collins C, Singla N, Gabrielson A, Bivalacqua TJ, Hahn N, et al. Intravesical gemcitabine and docetaxel (Gemdoce) in the treatment of BCG na\u00efve non-muscle invasive urothelial carcinoma of the bladder: updates from a phase 2 trial. AUA2022. https:\/\/doi.org\/10.1097\/JU.0000000000002642.15.","DOI":"10.1097\/JU.0000000000002642.15"},{"issue":"2","key":"1350_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/JU.0000000000000919","volume":"204","author":"GJ DeCastro","year":"2020","unstructured":"DeCastro GJ, Sui W, Pak JS, Lee SM, Holder D, Kates MM, et al. A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Guerin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder. J Urol. 2020;204(2):247\u201353. https:\/\/doi.org\/10.1097\/JU.0000000000000919.","journal-title":"J Urol"},{"issue":"6","key":"1350_CR45","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.eururo.2006.08.025","volume":"50","author":"A Giannantoni","year":"2006","unstructured":"Giannantoni A, Di Stasi SM, Chancellor MB, Costantini E, Porena M. New frontiers in intravesical therapies and drug delivery. Eur Urol. 2006;50(6):1183\u201393. https:\/\/doi.org\/10.1016\/j.eururo.2006.08.025.","journal-title":"Eur Urol."},{"issue":"1","key":"1350_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Di Stasi","year":"2006","unstructured":"Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7(1):43\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(05)70472-1.","journal-title":"Lancet Oncol"},{"key":"1350_CR47","doi-asserted-by":"publisher","unstructured":"Juvet T, Mari A, Lajkosz K, Wallis CJ, Kuk C, Erlich A, et al. Sequential administration of Bacillus Calmette-Guerin (BCG) and electromotive drug administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. Urol Oncol. 2020;38(11):850 e9- e15. https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.031.","DOI":"10.1016\/j.urolonc.2020.06.031"},{"issue":"1","key":"1350_CR48","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"M Racioppi","year":"2018","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF. Electromotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer. 2018;18(1):1224. https:\/\/doi.org\/10.1186\/s12885-018-5134-7.","journal-title":"BMC Cancer"},{"key":"1350_CR49","doi-asserted-by":"publisher","unstructured":"Pijpers OM, Hendricksen K, Mostafid H, de Jong FC, Rosier M, Mayor N, et al. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol. 2022;40(2):62 e13\u201362 e20. https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.019.","DOI":"10.1016\/j.urolonc.2021.07.019"},{"issue":"4","key":"1350_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.euf.2019.09.006","volume":"6","author":"DC Grimberg","year":"2020","unstructured":"Grimberg DC, Shah A, Inman BA. Overview of Taris GemRIS, a novel drug delivery system for bladder cancer. Eur Urol Focus. 2020;6(4):620\u20132. https:\/\/doi.org\/10.1016\/j.euf.2019.09.006.","journal-title":"Eur Urol Focus"},{"key":"1350_CR51","doi-asserted-by":"publisher","unstructured":"Heijden MSVD, Cutie ,Hampras CS, Stewart ICR, Acharya M, et al. SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin who are ineligible for or decline radical cystectomy. ASCO Genitourinary Cancers Symposium2022. J Clin Oncol.\u00a02022;40(6). https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS593.","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS593"},{"key":"1350_CR52","doi-asserted-by":"publisher","unstructured":"Peter C. Black, Tangen C, Singh P, McConkey DJ, Lucia S, Lowrance WT, et al. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). J Clin Oncol. 2020;38; 5022\u20135022. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5022.","DOI":"10.1200\/JCO.2020.38.15_suppl.5022"},{"issue":"4","key":"1350_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/jamaoncol.2020.6142","volume":"7","author":"J Gill","year":"2021","unstructured":"Gill J, Prasad V. Pembrolizumab for non-muscle-invasive bladder cancer-a costly therapy in search of evidence. JAMA Oncol. 2021;7(4):501\u20132. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6142.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1350_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","volume":"82","author":"M Roumiguie","year":"2022","unstructured":"Roumiguie M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Bohle A, et al. International Bladder Cancer Group Consensus statement on clinical trial design for patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle-invasive bladder cancer. Eur Urol. 2022;82(1):34\u201346. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.005.","journal-title":"Eur Urol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01350-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01350-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01350-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:02:03Z","timestamp":1744196523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01350-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1350"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01350-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"20 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human without informed consent or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"ICMJE disclosure forms are provided. SSC has consulted for the following: Urogen, Merck, Janssen, Pfizer, and ImmunityBio. Vanderbilt University Medical Center is a trial site for TAR-200.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}